70 related articles for article (PubMed ID: 8892744)
1. Hematologic benefits of 1-hydroxyvitamin D3 in an elderly patient with chronic myelodysplastic syndrome.
Motomura S; Fujisawa S; Tsunooka S; Fujimaki K; Mohri H; Okubo T
Am J Hematol; 1996 Oct; 53(2):143-4. PubMed ID: 8892744
[No Abstract] [Full Text] [Related]
2. Effect of low-dose 1-hydroxyvitamin D3 in a patient with myelodysplasia after induction therapy for acute myelocytic leukemia.
Fujisawa S; Motomura S; Sakai R; Tomita N; Fujimaki K; Mohri H; Okubo T
Anticancer Drugs; 1997 Jun; 8(5):466-7. PubMed ID: 9215609
[No Abstract] [Full Text] [Related]
3. [Treatment of myelodysplastic syndrome and acute myelogenous leukemia with vitamin D3 (1 alpha(OH)D3)].
Taoka T; Hamamoto T; Okuda Y; Hata Y; Kubota Y; Tanaka T; Irino S; Miyazaki T; Ohbayashi S
Rinsho Ketsueki; 1987 Jun; 28(6):830-8. PubMed ID: 3478504
[No Abstract] [Full Text] [Related]
4. Danazol therapy in myelodysplastic syndromes.
Pozzato G; Franzin F; Moretti M; Campanacci L
Haematologica; 1992; 77(1):96. PubMed ID: 1398293
[No Abstract] [Full Text] [Related]
5. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid.
Pilatrino C; Cilloni D; Messa E; Morotti A; Giugliano E; Pautasso M; Familiari U; Cappia S; Pelicci PG; Lo Coco F; Saglio G; Guerrasio A
Cancer; 2005 Jul; 104(1):101-9. PubMed ID: 15895376
[TBL] [Abstract][Full Text] [Related]
6. Trilineage response to recombinant human granulocyte colony-stimulating factor administration in a patient with myelodysplastic syndrome.
Rey C; Bader-Meunier B; Tertian G; Mielot F; Tchernia G; Yver A
Am J Hematol; 1993 May; 43(1):76-7. PubMed ID: 7686335
[No Abstract] [Full Text] [Related]
7. Therapeutic trial of hematological disorders with intermittent administration of high-dose 1-alpha-hydroxyvitamin D3.
Imai Y; Tsutsumi M; Tsunenari T; Nishikawa M; Matsui T; Natazuka T; Fujita T
Contrib Nephrol; 1991; 91():95-101. PubMed ID: 1800016
[TBL] [Abstract][Full Text] [Related]
8. The effect of 1-hydroxyvitamin D3 for prolongation of leukemic transformation-free survival in myelodysplastic syndromes.
Motomura S; Kanamori H; Maruta A; Kodama F; Ohkubo T
Am J Hematol; 1991 Sep; 38(1):67-8. PubMed ID: 1897516
[TBL] [Abstract][Full Text] [Related]
9. Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes.
Stasi R; Amadori S
Br J Haematol; 2002 Feb; 116(2):334-7. PubMed ID: 11841434
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of myelodysplastic syndrome with alfacalcidol].
Tagawa M; Ito H; Kuriyama K; Tomonaga M; Ichimaru M
Gan To Kagaku Ryoho; 1987 Nov; 14(11):3160-2. PubMed ID: 3674901
[No Abstract] [Full Text] [Related]
11. Treatment of myelodysplastic syndrome with 1.25-dihydroxy-vitamin D3.
Richard C; Mazo E; Cuadrado MA; Iriondo A; Bello C; Gandarillas MA; Zubizarreta A
Am J Hematol; 1986 Oct; 23(2):175-8. PubMed ID: 3755864
[TBL] [Abstract][Full Text] [Related]
12. Fluctuations of haemoglobin values in myelodysplastic syndrome.
Demiroglu H; Dündar S
N Z Med J; 1996 Mar; 109(1017):82-3. PubMed ID: 8606829
[No Abstract] [Full Text] [Related]
13. Platelet mass has prognostic value in patients with myelodysplastic syndromes.
Bowles KM; Warner BA; Baglin TP
Br J Haematol; 2006 Oct; 135(2):198-200. PubMed ID: 16939490
[TBL] [Abstract][Full Text] [Related]
14. Platelet morphology, platelet mass, platelet count and prognosis in patients with myelodysplastic syndromes.
Germing U; Platzbecker U; Giagounidis A; Aul C
Br J Haematol; 2007 Aug; 138(3):399-400. PubMed ID: 17555472
[No Abstract] [Full Text] [Related]
15. Activity of sirolimus in patients with myelodysplastic syndrome--results of a pilot study.
Platzbecker U; Haase M; Herbst R; Hänel A; Voigtmann K; Thiede CH; Mohr B; Schleyer E; Leopold T; Orth M; Hänel M; Ehninger G; Bornhäuser M
Br J Haematol; 2005 Mar; 128(5):625-30. PubMed ID: 15725083
[TBL] [Abstract][Full Text] [Related]
16. A rise of erythrocytes and platelets in a patient with myelodysplastic syndrome during the administration of G-CSF.
Washizuka T; Koike T; Toba K; Nagai K; Takahashi M; Shibata A
Am J Hematol; 1992 Feb; 39(2):153-4. PubMed ID: 1372467
[No Abstract] [Full Text] [Related]
17. Copper deficiency: an important consideration in the differential diagnosis of myelodysplastic syndrome.
Fong T; Vij R; Vijayan A; DiPersio J; Blinder M
Haematologica; 2007 Oct; 92(10):1429-30. PubMed ID: 18024379
[TBL] [Abstract][Full Text] [Related]
18. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
[TBL] [Abstract][Full Text] [Related]
19. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.
Lyons RM; Cosgriff TM; Modi SS; Gersh RH; Hainsworth JD; Cohn AL; McIntyre HJ; Fernando IJ; Backstrom JT; Beach CL
J Clin Oncol; 2009 Apr; 27(11):1850-6. PubMed ID: 19255328
[TBL] [Abstract][Full Text] [Related]
20. Myelodysplasia diagnosed during pregnancy with temporary haematological improvement after delivery.
Gidiri M; Masson EA; Ali S; Freites J; Carter C; Lindow SW
J Obstet Gynaecol; 2009 Oct; 29(7):665-7. PubMed ID: 19757280
[No Abstract] [Full Text] [Related]
[Next] [New Search]
